Total Cost of Revenue
United Therapeutics Total Cost of Revenue increased by 29.0% to $133.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 44.2%, from $92.50M to $133.40M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 33.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Detailed definition
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Peer comparison
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.20M | $27.70M | $34.60M | $25.90M | $29.70M | $37.20M | $58.80M | $52.30M | $64.10M | $70.10M | $71.00M | $72.90M | $77.80M | $83.10M | $75.90M | $92.50M | $87.60M | $100.90M | $103.40M | $133.40M |
| QoQ Change | — | -25.5% | +24.9% | -25.1% | +14.7% | +25.3% | +58.1% | -11.1% | +22.6% | +9.4% | +1.3% | +2.7% | +6.7% | +6.8% | -8.7% | +21.9% | -5.3% | +15.2% | +2.5% | +29.0% |
| YoY Change | — | — | — | — | -20.2% | +34.3% | +69.9% | +101.9% | +115.8% | +88.4% | +20.7% | +39.4% | +21.4% | +18.5% | +6.9% | +26.9% | +12.6% | +21.4% | +36.2% | +44.2% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso DPI | $37.60M | $39.10M | $38.40M | $48.10M | $48.50M | $55.30M | $58.70M | $83.20M |
| Remodulin | $12.80M | $13.30M | $13.40M | $13.80M | $14.30M | $13.10M | $8.10M | $16.10M |
| Nebulized Tyvaso | $8.40M | $9.40M | $7.40M | $8.50M | $5.60M | $6.70M | $6.40M | $8.60M |
| Orenitram | $5.90M | $7.60M | $5.70M | $8.30M | $6.70M | $6.80M | $6.90M | $7.40M |
| Unituxin | $3.80M | $4.80M | $2.20M | $5.20M | $2.80M | $3.60M | $5.90M | $5.00M |
| Adcirca | $2.60M | $3.10M | $1.80M | $2.60M | $2.70M | $4.40M | $3.40M | $1.00M |
| Total | $77.80M | $83.10M | $75.90M | $92.50M | $87.60M | $100.90M | $103.40M | $133.40M |
Tyvaso was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Cost of Revenue at Other Companies
Frequently Asked Questions
- What is United Therapeutics's total cost of revenue?
- United Therapeutics (UTHR) reported total cost of revenue of $133.40M in Q1 2026.
- How has United Therapeutics's total cost of revenue changed year-over-year?
- United Therapeutics's total cost of revenue increased by 44.2% year-over-year, from $92.50M to $133.40M.
- What is the long-term trend for United Therapeutics's total cost of revenue?
- Over 4 years (2021 to 2025), United Therapeutics's total cost of revenue has grown at a 33.1% compound annual growth rate (CAGR), from $122.50M to $384.40M.
- What does total cost of revenue mean?
- The direct costs incurred to produce the goods or services that a company sold during a specific period.